WASHINGTON UNIVERSITY AIDS CLINICAL TRIALS UNIT

华盛顿大学艾滋病临床试验中心

• 批准号: 8402793
• 负责人: DAVID B CLIFFORD
• 金额: $ 141.56万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-01 至 2014-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8402793
• 关键词: AIDS clinical trial group; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Adolescent; Affect; Area; Cardiovascular system; Childhood; Clinical; Clinical Management; Clinical Research; Clinical Trials Unit; Communities; Comorbidity; Counseling; Country; Development; Disease; Enrollment; Funding; HIV; HIV Infections; HIV therapy; Head; Health; Hepatitis; Infection prevention; International; Leadership; Metabolic; Neurologic; Participant; Persons; Population; Prevention; Protocols documentation; Recruitment Activity; Research; Structure; System; Time; Translational Research; Translations; Universities; Vaccine Research; Vertical Disease Transmission; Washington; Work; clinical research site; drug development; improved; medical schools; outreach; screening; vaccine development

DESCRIPTION (provided by applicant): This application will continue the contributions of an existing AIDS Clinical Trails Unit at Washington University School of Medicine in St. Louis for the next seven years. We propose a Clinical Trial Unit with an administrative structure led by Dr. David Clifford facilitating active contribution to the AIDS Clinical Trials Group (ACTG) network (100%) proposed in an application responding to RFA AI-05-001 headed by Dr. Constance Benson. We will conduct clinical research by recruiting, screening, and enrolling research participants in trials responding to clinical research plans in the following areas: (1) Translational Research/Drug Development, (-25) (2) Optimization of Clinical Management, Including Co-Morbidities,(~55%) (2)Prevention of Mother-to-Child Transmission(~10%) (4) Vaccine Research and Development. (~5%) and (5) Prevention of Infection (5%). This application describes a single Clinical Research Site (CRS) at Washington University School of Medicine that will carry out all portions of this research agenda. The CRS application includes plans for recruiting, screening, and enrolling 20 subjects in typical protocols in the above research areas, as well as ongoing work supporting continuing trials organized by the ACTG system with in excess of100 participating subjects at the present time. The St. Louis CTU will also contribute to scientific leadership assisting development of translational research with particular emphasis on the co-morbidities including neurologic conditions, hepatitis, cardiovascular and metabolic complications. Additional scientific leadership and expertise will continue to be developed in areas of new HIV therapies and pediatric and adolescent manifestations of HIV disease. Ongoing support for a vital Community Advisory Board will be continued under this application, assuring the constructive engagement for advise and counsel from affected populations, as well as providing outreach and educational support to affected populations. Funding this application will provide for ongoing contributions of the Washington University AIDS research community in translation of critical scientific concepts to optimal implementation to the benefit of all persons with HIV infection. We anticipate improvements in therapy that will improve the health in our own community, country, and in the much larger international community affected by HIV/AIDS. ADMINISTRATIVE COMPONENT:

描述（由申请人提供）：本申请将在未来七年内继续圣路易斯华盛顿大学医学院现有艾滋病临床试验单位的贡献。我们建议成立一个临床试验部门，其行政结构由大卫克利福德博士领导，以促进对艾滋病临床试验组（ACTG）网络（100%）的积极贡献，该网络是在对由康斯坦斯·本森博士领导的RFA AI-05-001的申请做出回应时提出的。我们将通过招募、筛选和招募研究参与者参与以下领域的临床研究计划进行临床研究：（1）转化研究/药物开发，（~ 25）（2）优化临床管理，包括合并症，（~55%）（2）预防母婴传播（~10%）（4）疫苗研究和开发。（约5%）和（5）预防感染（5%）。本申请描述了华盛顿大学医学院的一个临床研究中心（CRS），该中心将执行本研究议程的所有部分。CRS申请包括在上述研究领域的典型方案中招募、筛选和入组20名受试者的计划，以及正在进行的支持ACTG系统组织的持续试验的工作，目前参与受试者超过100名。圣路易斯CTU还将为科学领导做出贡献，协助转化研究的发展，特别强调合并症，包括神经系统疾病，肝炎，心血管和代谢并发症。在艾滋病毒新疗法和艾滋病毒疾病的儿科和青少年表现方面，将继续发展更多的科学领导力和专门知识。在这一申请下，将继续为一个至关重要的社区咨询委员会提供持续支助，确保建设性地参与受影响人口的咨询和建议，并向受影响人口提供外联和教育支助。资助这一应用将提供华盛顿大学艾滋病研究界在翻译关键的科学概念，以最佳的执行，以造福于所有艾滋病毒感染者的持续贡献。我们期待着治疗方法的改进，这将改善我们自己的社区、国家和受艾滋病毒/艾滋病影响的更大的国际社会的健康状况。 行政部门：